US EditionBoehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025
- Boehringer Ingelheim will present new data on the investigational therapies obrixtamig and zongertinib at the 2025 ASCO Annual Meeting in Chicago, IL.
- This follows their multi-pronged strategy to tackle difficult-to-treat cancers by targeting key drivers HER2 and DLL3 due to limited options and poor outcomes.
- Phase I data showed obrixtamig achieved a 40% objective response rate and 7.9 months median duration of response in 60 patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas.
- Zongertinib, an oral HER2-targeted tyrosine kinase inhibitor, led to a notable increase in patients' physical capabilities—measured by activities such as walking and daily task performance—after 15 weeks of treatment in individuals with previously treated HER2-mutant advanced NSCLC, indicating meaningful improvements reported by patients.
- These findings underscore Boehringer Ingelheim’s broad oncology pipeline and support potential advances for cancers with high unmet medical need.
Insights by Ground AI
Does this summary seem wrong?
45 Articles
45 Articles
The Conway Daily Sun+44 Reposted by 44 other sources
Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025
Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study in previously treated patients with HER2 (ERRB2)-mutant advanced non-small cell lung cancer (NSCLC)…
Coverage Details
Total News Sources45
Leaning Left6Leaning Right4Center14Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 25%
C 58%
R 17%
Factuality
To view factuality data please Upgrade to Premium
